IMVT
Immunovant Inc
32.10$
-3.4%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
Immunovant Inc (IMVT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -124 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.1 | -3.4 | -7.4 | -0.5 | -0.2 | -0.3 | 0.0 | -23 | -14 | -24 | -23 | -22 | -21 | -20 | -32 | -33 | -66 | -20 | -46 | -56 | -47 | -60 | -47 | -60 | -76 | -89 | -100 | -111 | -117 | -103 | -92 | -95 | -124 | -414 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | |
| 0.4 | 0.5 | 0.2 | -0.3 | 0.0 | 0.0 | 0.0 | 1.8 | 4.0 | 3.4 | 6.0 | 5.5 | 3.9 | 8.4 | 10 | 12 | 7.7 | 8.2 | 8.9 | 7.5 | 11 | 11 | 10 | 9.7 | 13 | 13 | 12 | 12 | 19 | 13 | 13 | 11 | 14 | 51 | |
| 0.4 | 0.6 | 0.2 | – | 0.3 | 3.0 | 1.3 | 2.0 | 4.2 | 3.4 | 7.0 | 4.9 | 4.7 | 8.5 | 9.7 | 12 | 7.7 | 8.4 | 8.9 | 7.5 | 11 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 1.9 | 1.5 | -3.9 | 0.0 | 0.3 | 0.0 | -4.5 | 8.7 | -6.9 | 2.0 | 0.7 | 4.5 | 8.8 | -0.2 | 2.0 | -33 | 19 | 7.6 | -4.2 | 16 | -12 | -6.3 | 5.6 | -2.7 | 7.7 | -1.0 | -16 | -15 | 11 | 5.5 | 42 | 15 | 72 | |
| 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | -0.1 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | – | – | – | 0.0 | – | – | |
| – | – | – | – | 118 | 118 | -118 | 0.0 | – | – | – | – | – | 200 | – | – | 0.0 | – | 71 | 0.2 | 0.9 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 5.0 | 5.0 | 5.0 | – | 5.0 | 33 | 0.0 | 0.0 | -2.9 | -0.2 | -0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 5.1 | 8.5 | 14 | -177 | 117 | 0.0 | 0.1 | 0.1 | 194 | 188 | 0.4 | 0.8 | 0.1 | 200 | 0.0 | 0.0 | 0.0 | 71 | 71 | 0.2 | 0.9 | 0.1 | 470 | 1.5 | 0.7 | 0.7 | 2.5 | 451 | 2.9 | 25 | 565 | 3.6 | 20 | 613 | |
| 5.0 | 5.0 | 7.1 | -177 | 1.8 | -0.3 | 0.1 | -23 | 180 | 164 | -22 | -22 | -21 | 180 | -32 | -33 | -67 | -21 | 27 | -56 | -47 | -60 | 421 | -56 | -75 | -87 | -98 | 339 | -115 | -77 | 473 | -92 | -104 | 199 | |
| -5.1 | -3.4 | -7.4 | -0.5 | -0.2 | -0.3 | 0.0 | -23 | -14 | -24 | -23 | -23 | -21 | -20 | -32 | -33 | -66 | -20 | -46 | -56 | -47 | -60 | -47 | -60 | -76 | -89 | -101 | -111 | -117 | -103 | -92 | -95 | -124 | -414 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.